Rockwell Medical, Inc. (RMTI)
USD 1.06
(-0.93%)
USD 1.06
(-0.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.45 Million USD | 186.88% |
| 2022 | -5.12 Million USD | -132.85% |
| 2021 | 15.61 Million USD | 163.1% |
| 2020 | -24.74 Million USD | -219.0% |
| 2019 | -7.75 Million USD | 65.85% |
| 2018 | -22.71 Million USD | -170.18% |
| 2017 | -8.4 Million USD | 51.07% |
| 2016 | -17.18 Million USD | 44.93% |
| 2015 | -31.19 Million USD | 52.59% |
| 2014 | -65.8 Million USD | -888.63% |
| 2013 | 8.34 Million USD | 277.17% |
| 2012 | -4.7 Million USD | 17.47% |
| 2011 | -5.7 Million USD | 53.43% |
| 2010 | -12.25 Million USD | 46.66% |
| 2009 | -22.97 Million USD | -327.18% |
| 2008 | -5.37 Million USD | 49.72% |
| 2007 | -10.69 Million USD | -443.8% |
| 2006 | -1.96 Million USD | -171.35% |
| 2005 | 2.75 Million USD | 84.45% |
| 2004 | 1.49 Million USD | -15.53% |
| 2003 | 1.76 Million USD | 26.99% |
| 2002 | 1.39 Million USD | -14.67% |
| 2001 | 1.63 Million USD | 1005.6% |
| 2000 | -180.32 Thousand USD | 83.61% |
| 1999 | -1.1 Million USD | 42.11% |
| 1998 | -1.9 Million USD | -2000.0% |
| 1997 | 100 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.54 Million USD | 69.23% |
| 2024 Q2 | 2.51 Million USD | -66.66% |
| 2023 Q3 | 7.11 Million USD | 335.31% |
| 2023 FY | 4.45 Million USD | 186.88% |
| 2023 Q2 | -3.02 Million USD | -166.44% |
| 2023 Q1 | 4.55 Million USD | 188.77% |
| 2023 Q4 | 4.45 Million USD | -37.4% |
| 2022 FY | -5.12 Million USD | -132.85% |
| 2022 Q3 | 9.28 Million USD | 234.76% |
| 2022 Q1 | 15.87 Million USD | 1.68% |
| 2022 Q2 | -6.88 Million USD | -143.38% |
| 2022 Q4 | -5.12 Million USD | -155.26% |
| 2021 Q1 | -9.69 Million USD | 60.82% |
| 2021 FY | 15.61 Million USD | 163.1% |
| 2021 Q2 | -5.06 Million USD | 47.76% |
| 2021 Q4 | 15.61 Million USD | 151.65% |
| 2021 Q3 | 6.2 Million USD | 222.51% |
| 2020 Q4 | -24.74 Million USD | 26.28% |
| 2020 Q1 | -13.61 Million USD | -75.51% |
| 2020 Q2 | -3.38 Million USD | 75.13% |
| 2020 Q3 | -33.56 Million USD | -891.14% |
| 2020 FY | -24.74 Million USD | -219.0% |
| 2019 FY | -7.75 Million USD | 65.85% |
| 2019 Q3 | -10.2 Million USD | 36.93% |
| 2019 Q2 | -16.18 Million USD | 9.62% |
| 2019 Q4 | -7.75 Million USD | 23.99% |
| 2019 Q1 | -17.9 Million USD | 18.12% |
| 2018 Q4 | -21.86 Million USD | -359.15% |
| 2018 Q1 | 10.58 Million USD | 225.93% |
| 2018 Q2 | 11.54 Million USD | 9.09% |
| 2018 Q3 | 8.43 Million USD | -26.95% |
| 2018 FY | -22.71 Million USD | -170.18% |
| 2017 Q4 | -8.4 Million USD | -116.23% |
| 2017 Q2 | -8.32 Million USD | 30.02% |
| 2017 FY | -8.4 Million USD | 51.07% |
| 2017 Q1 | -11.89 Million USD | 30.74% |
| 2017 Q3 | -3.88 Million USD | 53.31% |
| 2016 Q2 | -23.82 Million USD | 20.61% |
| 2016 Q4 | -17.18 Million USD | 10.95% |
| 2016 FY | -17.18 Million USD | 44.93% |
| 2016 Q3 | -19.29 Million USD | 19.01% |
| 2016 Q1 | -30 Million USD | 3.82% |
| 2015 Q4 | -31.19 Million USD | 5.95% |
| 2015 Q1 | -63.33 Million USD | 3.75% |
| 2015 FY | -31.19 Million USD | 52.59% |
| 2015 Q2 | -37.14 Million USD | 41.35% |
| 2015 Q3 | -33.17 Million USD | 10.7% |
| 2014 Q1 | 19.67 Million USD | 135.83% |
| 2014 Q2 | 17.59 Million USD | -10.6% |
| 2014 Q3 | 16.99 Million USD | -3.37% |
| 2014 FY | -65.8 Million USD | -888.63% |
| 2014 Q4 | -65.8 Million USD | -487.11% |
| 2013 Q1 | -5.77 Million USD | -22.58% |
| 2013 Q4 | 8.34 Million USD | 787.95% |
| 2013 Q3 | -1.21 Million USD | 94.21% |
| 2013 FY | 8.34 Million USD | 277.17% |
| 2013 Q2 | -20.95 Million USD | -262.93% |
| 2012 Q1 | -13.63 Million USD | -138.92% |
| 2012 Q4 | -4.7 Million USD | -302.11% |
| 2012 Q3 | -1.17 Million USD | 81.89% |
| 2012 Q2 | -6.46 Million USD | 52.58% |
| 2012 FY | -4.7 Million USD | 17.47% |
| 2011 FY | -5.7 Million USD | 53.43% |
| 2011 Q4 | -5.7 Million USD | 32.15% |
| 2011 Q3 | -8.41 Million USD | 9.59% |
| 2011 Q2 | -9.3 Million USD | -17.28% |
| 2011 Q1 | -7.93 Million USD | 35.18% |
| 2010 FY | -12.25 Million USD | 46.66% |
| 2010 Q2 | -24.16 Million USD | 1.72% |
| 2010 Q1 | -24.58 Million USD | -7.01% |
| 2010 Q3 | -23.62 Million USD | 2.24% |
| 2010 Q4 | -12.23 Million USD | 48.2% |
| 2009 Q3 | -2.67 Million USD | 16.51% |
| 2009 Q1 | -3.18 Million USD | 40.78% |
| 2009 Q2 | -3.2 Million USD | -0.51% |
| 2009 Q4 | -22.97 Million USD | -759.6% |
| 2009 FY | -22.97 Million USD | -327.18% |
| 2008 FY | -5.37 Million USD | 49.72% |
| 2008 Q1 | -10.29 Million USD | 3.73% |
| 2008 Q3 | -7.23 Million USD | 23.36% |
| 2008 Q4 | -5.37 Million USD | 25.67% |
| 2008 Q2 | -9.44 Million USD | 8.33% |
| 2007 Q3 | 2.27 Million USD | 24.93% |
| 2007 FY | -10.69 Million USD | -443.8% |
| 2007 Q1 | 1.12 Million USD | 157.29% |
| 2007 Q2 | 1.81 Million USD | 61.48% |
| 2007 Q4 | -10.69 Million USD | -570.51% |
| 2006 Q3 | -3.17 Million USD | 16.58% |
| 2006 Q4 | -1.96 Million USD | 38.04% |
| 2006 Q1 | -4.57 Million USD | -265.8% |
| 2006 Q2 | -3.8 Million USD | 16.73% |
| 2006 FY | -1.96 Million USD | -171.35% |
| 2005 Q3 | 1.96 Million USD | 137.4% |
| 2005 Q2 | 827.44 Thousand USD | 2.63% |
| 2005 FY | 2.75 Million USD | 84.45% |
| 2005 Q1 | 806.25 Thousand USD | -46.06% |
| 2005 Q4 | 2.75 Million USD | 40.36% |
| 2004 Q4 | 1.49 Million USD | -0.94% |
| 2004 Q1 | 1.45 Million USD | -17.76% |
| 2004 Q2 | 1.45 Million USD | -0.36% |
| 2004 Q3 | 1.5 Million USD | 4.06% |
| 2004 FY | 1.49 Million USD | -15.53% |
| 2003 FY | 1.76 Million USD | 26.99% |
| 2003 Q1 | 1.52 Million USD | 9.33% |
| 2003 Q3 | 1.62 Million USD | -2.08% |
| 2003 Q2 | 1.65 Million USD | 8.69% |
| 2003 Q4 | 1.76 Million USD | 9.14% |
| 2002 Q1 | 1.42 Million USD | -12.7% |
| 2002 Q3 | 766.28 Thousand USD | -57.45% |
| 2002 Q4 | 1.39 Million USD | 81.84% |
| 2002 Q2 | 1.8 Million USD | 26.33% |
| 2002 FY | 1.39 Million USD | -14.67% |
| 2001 Q3 | 802.86 Thousand USD | 108.14% |
| 2001 Q1 | 339.58 Thousand USD | 288.32% |
| 2001 FY | 1.63 Million USD | 1005.6% |
| 2001 Q4 | 1.63 Million USD | 103.4% |
| 2001 Q2 | 385.73 Thousand USD | 13.59% |
| 2000 Q3 | -445.98 Thousand USD | 7.07% |
| 2000 FY | -180.32 Thousand USD | 83.61% |
| 2000 Q1 | -835.5 Thousand USD | 24.04% |
| 2000 Q2 | -479.91 Thousand USD | 42.56% |
| 2000 Q4 | -180.32 Thousand USD | 59.57% |
| 1999 Q4 | -1.1 Million USD | -10.0% |
| 1999 Q2 | -1.1 Million USD | 15.38% |
| 1999 FY | -1.1 Million USD | 42.11% |
| 1999 Q1 | -1.3 Million USD | 31.58% |
| 1999 Q3 | -1 Million USD | 9.09% |
| 1998 Q2 | -2.5 Million USD | 28.57% |
| 1998 Q3 | -2.1 Million USD | 16.0% |
| 1998 Q4 | -1.9 Million USD | 9.52% |
| 1998 FY | -1.9 Million USD | -2000.0% |
| 1998 Q1 | -3.5 Million USD | -3600.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1997 Q4 | 100 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -141.947% |
| Alpha Teknova, Inc. | 1.97 Million USD | -125.735% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 95.27% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 94.055% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 98.976% |
| Cosmos Health Inc. | 8.59 Million USD | 48.13% |
| Journey Medical Corporation | -9.7 Million USD | 145.896% |
| Embecta Corp. | 1.31 Billion USD | 99.66% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 99.029% |
| Dynavax Technologies Corporation | 106.63 Million USD | 95.821% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 103.406% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 98.97% |
| PainReform Ltd. | -7.95 Million USD | 156.05% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 128.501% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 128.501% |
| SCYNEXIS, Inc. | -19.35 Million USD | 123.028% |
| Safety Shot Inc | -2.28 Million USD | 295.064% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 147.255% |
| Procaps Group, S.A. | 242.93 Million USD | 98.166% |
| Theratechnologies Inc. | 24.87 Million USD | 82.084% |
| Harrow Health, Inc. | 116.41 Million USD | 96.172% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 276.825% |
| Biofrontera Inc. | 4.05 Million USD | -9.862% |
| DURECT Corporation | -7.65 Million USD | 158.218% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 113.291% |
| Cronos Group Inc. | -663.32 Million USD | 100.672% |
| OptiNose, Inc. | 58.06 Million USD | 92.326% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 99.285% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 130.579% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 185.923% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 70.319% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 170.067% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -4069.981% |
| Radius Health, Inc. | 359.28 Million USD | 98.76% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -2159.532% |
| ProPhase Labs, Inc. | 19.23 Million USD | 76.829% |
| Phibro Animal Health Corporation | 454.84 Million USD | 99.02% |
| Procaps Group S.A. | 242.93 Million USD | 98.166% |
| Alvotech | 1.06 Billion USD | 99.581% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -21.153% |
| Viatris Inc. | 17.13 Billion USD | 99.974% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 191.368% |
| SIGA Technologies, Inc. | -148.68 Million USD | 102.997% |
| Tilray Brands, Inc. | 158.97 Million USD | 97.197% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 96.344% |
| Shineco, Inc. | 29.29 Million USD | 84.787% |
| PetIQ, Inc. | 351.93 Million USD | 98.734% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 253.58% |
| Incannex Healthcare Limited | -5.48 Million USD | 181.24% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 97.487% |
| Alimera Sciences, Inc. | 55.3 Million USD | 91.943% |
| Silver Spike Investment Corp. | -32.61 Million USD | 113.664% |
| Assertio Holdings, Inc. | -32.52 Million USD | 113.699% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 399.317% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 188.057% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 192.563% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 154.252% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -5.668% |
| Hempacco Co., Inc. | 13.61 Million USD | 67.271% |
| Talphera, Inc. | -5.72 Million USD | 177.888% |
| Alvotech | 1.06 Billion USD | 99.581% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 37.635% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 104.608% |
| Currenc Group, Inc. | -16.57 Million USD | 126.887% |
| Kamada Ltd. | -46.43 Million USD | 109.597% |
| Indivior PLC | -33.95 Million USD | 113.124% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -1610.071% |
| Flora Growth Corp. | -713 Thousand USD | 724.965% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 154.252% |
| Evolus, Inc. | 63.7 Million USD | 93.006% |
| HUTCHMED (China) Limited | -197.45 Million USD | 102.257% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 99.07% |
| Akanda Corp. | 3.9 Million USD | -14.113% |